Investigation launched into CVRx over DOJ probe, sales issues, and sudden CRO firing
Hagens Berman has initiated an investigation into CVRx Inc. following a U.S. Department of Justice Civil Investigative Demand regarding potential false claims and kickbacks tied to its Barostim heart failure device. This comes after CVRx drastically cut its 2026 revenue guidance due to sales force problems and reduced Medicare Advantage approvals, leading to a 59% stock drop and the abrupt termination of its Chief Revenue Officer. The investigation will examine these events for possible internal issues and investor misinformation.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Hagens Berman, a national securities law firm, is investigating CVRx Inc. (CVRX) for potential securities fraud after a 59% stock drop. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand, significant cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer. Investors with substantial losses are encouraged to contact the firm.
Law firm investigates CVRx for possible securities violations after revenue guidance cut and DOJ probe.
Block & Leviton is investigating CVRx, Inc. for potential securities law violations. This comes after CVRx lowered its full-year revenue guidance due to sales-force issues and reimbursement problems, and also disclosed a Department of Justice civil investigative demand regarding its sales and marketing practices. The investigation seeks to determine if investors were adequately informed about these issues earlier.
Cantor Fitzgerald Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5
Cantor Fitzgerald has reiterated its "Buy" rating for CVRx Inc (CVRX.US) but has reduced the target price for the stock to $5. This decision indicates a continued positive outlook on the company's prospects despite a lower price expectation.
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com
Cantor Fitzgerald lowered its price target for CVRx Inc (NASDAQ:CVRX) to $5.00 from $13.00, citing near-term sales execution and reimbursement pressures, despite maintaining an "Overweight" rating. The company's Q2 2026 results reflected challenges in specific regions with new leadership and hiring pressures, leading to a lowered 2026 guidance. Despite these headwinds, CVRx maintains an 87% gross profit margin and strong liquidity.
Cantor Fitzgerald Issues Pessimistic Forecast for CVRx (NASDAQ:CVRX) Stock Price
Cantor Fitzgerald has cut its price target for CVRx (NASDAQ:CVRX) from $13 to $5, although it maintains an "overweight" rating, suggesting a significant upside. This reduction aligns with a general weakening of analyst sentiment, leading to a consensus "Hold" rating and an average price target of $5.30 for CVRx. The company recently reported a quarterly loss worse than estimates and a negative net margin, impacting its stock performance.
Cvrx COO Brent Binkowski sells $3,338 in company stock
CVRx COO Brent Binkowski sold 1,309 shares of the company's stock for a total of $3,338 in a sell-to-cover transaction to meet tax obligations. Following this sale, Binkowski directly holds 30,291 shares. The company recently reported a 16% increase in Q2 revenue but lowered its full-year outlook due to sales force and reimbursement challenges, leading Piper Sandler to downgrade its stock rating.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Hagens Berman, a national shareholder rights litigation firm, has initiated an investigation into CVRx Inc. (CVRX) for potential federal securities law violations. This investigation follows a 59% stock drop after the company disclosed a U.S. Department of Justice Civil Investigative Demand, severe revenue guidance cuts, sales force disruption, and the unexpected termination of its Chief Revenue Officer. The firm is encouraging CVRx investors who have experienced substantial losses to contact them to evaluate their legal rights and recovery options, and is also seeking whistleblowers with non-public information.
CVRx, Inc. (CVRX) investor Jorey Chernett discloses 5.5% beneficial stake
Investor Jorey Chernett has disclosed a 5.5% beneficial ownership stake in CVRx, Inc. (CVRX), holding 1,461,750 shares of common stock. This ownership grants Chernett sole voting and dispositive power over these shares, based on CVRx's 26,641,597 outstanding shares as of July 30, 2026. The disclosure was made via a SCHEDULE 13G filing, indicating a passive investment.
Insider Purchase: CHIEF OPERATING OFFICER of $CVRX Buys 26,223 Shares
The Chief Operating Officer of CVRX (CVRX) recently purchased 26,223 shares of the company's stock. This insider transaction signals confidence in the company's future prospects from a key executive.
Cvrx COO Brent Binkowski sells $3,338 in company stock
Brent Binkowski, COO of CVRx, Inc., sold 1,309 shares of company stock for $3,338 in a sell-to-cover transaction to satisfy tax obligations. This sale comes as CVRx reported increased Q2 revenue but lowered its full-year outlook due to sales force and reimbursement challenges, leading Piper Sandler to downgrade the stock.
Cvrx COO Brent Binkowski buys $76,432 in company stock
CVRx COO Brent Binkowski purchased 26,223 shares of the company's common stock for $76,432 on August 13, 2026, increasing his direct ownership to 56,514 shares. This insider purchase occurs while the stock is near its 52-week low, with InvestingPro suggesting it is undervalued. The company recently reported Q2 revenue growth but lowered its full-year outlook due to sales force issues and reimbursement challenges, leading to a downgrade by Piper Sandler.
CVRx (NASDAQ:CVRX) COO Brent Binkowski Buys 26,223 Shares of Stock
CVRx COO Brent Binkowski recently purchased 26,223 shares of CVRx stock for $2.91 per share, increasing his total holdings to 56,514 shares. This purchase followed a sale of 1,309 shares the previous day. Despite the insider buying and a 7.7% stock increase, CVRx continues to face profitability challenges and has received several analyst downgrades, resulting in a consensus "Hold" rating with an average price target of $6.90.
Insider Purchase: CHIEF OPERATING OFFICER of $CVRX Buys 26,223 Shares
Brent Binkowski, the Chief Operating Officer of CVRX, purchased 26,223 shares of the company stock for an estimated $76,432, increasing his holdings by 86.6%. This transaction was part of 9 insider trades in the past six months, with 3 purchases and 6 sales. The article also details recent hedge fund activity in CVRX, showing both increased and decreased institutional investor positions.
CVRx (CVRX) COO Brent Binkowski purchases 26,223 shares in open-market buy
Brent Binkowski, Chief Operating Officer of CVRx, Inc. (CVRX), purchased 26,223 shares of the company's common stock on August 13, 2026. The open-market transactions occurred at a weighted average price of $2.9147 per share, with individual trade prices ranging from $2.87 to $2.96. Following these purchases, Binkowski directly holds 56,514 shares of CVRx common stock.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Hagens Berman, a national securities law firm, has initiated an investigation into CVRx Inc. (NASDAQ: CVRX) for potential federal securities law violations following a 59% stock drop. The investigation comes after CVRx disclosed a U.S. Department of Justice Civil Investigative Demand, significant cuts to revenue guidance, commercial sales force disruption, and the sudden termination of its Chief Revenue Officer. Investors who suffered substantial losses are encouraged to contact the firm to evaluate their legal rights.
Block & Leviton investigates CVRx for possible securities law violations after revenue guidance cut.
Block & Leviton is investigating CVRx, Inc. for potential securities law violations after the company reduced its full-year revenue guidance. The lowered guidance is attributed to sales execution issues, high employee turnover, and reimbursement challenges. Additionally, CVRx revealed a Department of Justice inquiry into its sales and marketing practices, prompting the investigation to determine if the company and its executives adequately informed investors of these problems.
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5
CCORF has reiterated its Buy rating for CVRx Inc (CVRX.US) but has revised its target price downwards to $5. This adjustment indicates a continued positive outlook on the company's stock, despite a reduction in the expected price target.
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRx is focusing on expanding the adoption of its Barostim therapy for heart failure, targeting the "forgotten middle" of patients with NYHA Class II/III heart failure. The company is refining its commercial strategy, improving reimbursement particularly with Medicare, and has launched the large-scale BENEFIT-HF trial to further evaluate the therapy and potentially triple its addressable market. Despite some commercial challenges, CVRx remains committed to its strategy, viewing Barostim as crucial for patients who fall between drug therapy and advanced interventions.
CVRx chief revenue officer exits amid slowing sales and execution concerns
CVRx Inc. has announced the departure of its chief revenue officer following a reduction in its full-year revenue guidance. The company attributes the lowered outlook to employee turnover and productivity issues, which have impacted sales of its primary product, Barostim, a device for heart failure. CVRx remains heavily reliant on this single product.
CVRx, Inc. $CVRX Shares Acquired by Royal Bank of Canada
Royal Bank of Canada significantly increased its stake in CVRx, Inc. (NASDAQ:CVRX) during the first quarter, acquiring over 696,000 additional shares to own 2.66% of the company. Despite this, analyst sentiment has weakened, with several downgrades to "Hold" or "Neutral" and an average price target of $6.90. CVRx reported a slight earnings per share miss but exceeded revenue expectations, though it faces substantial losses and negative profitability metrics.
CVRx, Inc. Investors With Losses Should Contact Block & Leviton About Securities Fraud Investigation
Block & Leviton is investigating CVRx, Inc. (Nasdaq:CVRX) for potential securities law violations after the company cut its full-year revenue guidance, citing sales-force issues, elevated turnover, and a prolonged reimbursement challenge. The investigation also concerns a civil investigative demand from the Department of Justice regarding sales and marketing practices. Investors who purchased CVRx common stock and have experienced losses are encouraged to contact Block & Leviton to learn about recovering their losses.
CVRX: Execution improvements and payer wins position the therapy for broader adoption and growth
CVRx, Inc. (CVRX) is addressing execution challenges in sales onboarding for its novel heart failure device, which targets a large and underserved market. The company is poised for broader adoption and growth due to strong Medicare coverage and anticipated improved payer coverage following Humana's policy. Leadership expresses confidence in their strategy and the market potential.
CVRx to replace CRO after cutting guidance and DOJ civil inquiry
CVRx announced it has let go of its Chief Revenue Officer Robert John and appointed Paul Verrastro as interim head of sales, following a disappointing earnings report and a disclosed Department of Justice civil investigation into its sales and marketing practices. The company also cut its 2026 revenue guidance and is searching for a new Chief Financial Officer, Jared Oasheim, who resigned in June. CVRx shares have fallen significantly in the past week.
CV's Robert John departs as Chief Revenue Officer
Robert John, Chief Revenue Officer of CVRX, terminated his employment with the company effective August 10, 2026. He is entitled to severance pay and benefits as per his employment agreement. The reason for his departure and information regarding his replacement were not disclosed.
CVRx (CVRX) ousts CRO, installs interim sales head as outlook shifts
CVRx, Inc. announced the departure of Chief Revenue Officer Robert John and the appointment of Paul Verrastro as Interim Head of Sales, effective immediately. This leadership change is attributed to a revised commercial outlook and the need to improve commercial execution. Verrastro, with over 30 years of medical device sales and marketing experience, will lead the sales organization while a permanent successor is sought.
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into CVRx, Inc. (CVRX) after the company disclosed a civil investigative demand from the U.S. Department of Justice concerning sales and marketing practices, including potential false claims and kickbacks. This news, coupled with lowered full-year revenue guidance and issues with hiring and training, led to a significant drop in CVRx's stock price, injuring investors. Shareholders who lost money are encouraged to contact the law firm for more information regarding potential claims.
(CVRX) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis of Cvrx Inc. (NASDAQ: CVRX), highlighting weak sentiment across all horizons and a short bias. It details institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report suggests a breakdown is underway with elevated downside risk.
CVRx, Inc. (NASDAQ:CVRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
CVRx, Inc. (NASDAQ:CVRX) experienced a significant share price drop of 54% following its second-quarter results, which met revenue expectations but reported wider losses than anticipated. Analysts have subsequently lowered their revenue forecasts for 2026 and increased their per-share loss expectations, leading to a 47% reduction in the average price target to US$5.92. The company is now expected to see a revenue reduction of 7.6% annually by the end of 2026, lagging behind the broader industry's projected growth.
CVRx Falls To US$2.39, But Insiders Sold At Lower Price
The article discusses CVRx's recent stock price decline to US$2.39, highlighting that while the stock has fallen, insiders had sold shares at an even lower price of US$2.05 in the past year. This insider selling activity, despite the lower price point, raises questions about their confidence in the company's future prospects. The article implies that this trend could be a point of concern for potential investors.
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Hold" by Brokerages
CVRx, Inc. (NASDAQ:CVRX) has received a consensus "Hold" recommendation from six brokerages, with an average 12-month price target of $6.90. The company's stock recently fell significantly to $2.72 after reporting a $0.53-per-share quarterly loss and negative net margin, despite beating revenue expectations. Analysts have lowered ratings and price targets, and future revenue guidance indicates slowing growth, which could pressure the stock further.
CVRx (NASDAQ:CVRX) Rating Lowered to Sell at Wall Street Zen
CVRx (NASDAQ:CVRX) has had its rating lowered to "sell" by Wall Street Zen, with several other analysts also reducing their ratings due to concerns about profitability and execution. The company reported a quarterly loss and negative margins, leading to a cut in revenue guidance for the third quarter and full year 2026. Despite a consensus "hold" rating and a price target of $6.90, the stock has fallen significantly and trades near its 12-month low of $2.30.
IMA,CVRX Volatility & Greeks
This article provides detailed financial data and performance metrics for two companies, ImageneBio Inc (IMA) and CVRx Inc (CVRX). It includes information on their stock performance, market capitalization, income, sales, volatility, and various financial ratios, offering a snapshot of their current market standing.
Key facts: CVRx, Inc. Q2 revenue +16%; Humana adds Barostim
CVRx, Inc. (CVRX) reported Q2 revenue of $15.7 million, a 16% increase year-over-year, with U.S. sales up 21% to $14.8 million. The company achieved an 87% gross profit margin, resulting in a net loss of $14.0 million, and holds $64.6 million in cash. Additionally, Humana has expanded Medicare Advantage coverage for CVRx's Barostim device, marking a significant development for the device's reimbursement and market access.
CVRx, Inc. Stock 12‑Month Price Target Cut to $8, Implies 35% Upside
CVRx, Inc.'s stock 12-month price target has been lowered from $11.17 to $8, according to estimates from 5 analysts, with a range of $4 to $14 per share. This new target suggests a potential upside of approximately 35% from the August 6 closing price. Despite the target cut, the consensus rating from 7 covering analysts remains "Buy," with 5 Buys, 1 Hold, and 1 Sell.
Law firm probes CVRx over possible securities l...
A law firm is investigating CVRx, Inc. and its executives for potential securities law violations after the company cut its 2026 revenue guidance and disclosed a Department of Justice inquiry. The revenue guidance reduction was attributed to challenges such as high employee turnover, slow productivity, and issues with a major Medicare Advantage payer. The investigation aims to determine if investors were misled by misrepresented or withheld material information.
Piper Sandler cuts CVRx stock rating on sales, reimbursement issues
Piper Sandler downgraded CVRx Inc (NASDAQ:CVRX) to Neutral from Overweight and lowered its price target to $4.00 from $12.00, citing sales force issues and challenges in obtaining consistent reimbursement from its largest payer. While CVRx's second-quarter revenue surpassed estimates, the company reduced its full-year outlook due to these operational difficulties. Piper Sandler also noted that addressing these issues will take time and highlighted the company's quick cash burn despite a strong current ratio.
CVRx (CVRX) Stock Reels From Guidance Cut And Cash Burn Fears
CVRx (CVRX) stock dropped almost 60% after cutting its 2026 revenue guidance to US$58m-US$60m and providing softer Q3 guidance. Despite strong Q2 revenue of US$15.7m and high gross margins of 87%, the company reported a US$14.0m net loss and continues to burn cash, raising concerns about its funding gap and financial fragility. Investors are now questioning the long-term viability of this one-product medtech company amidst commercial hiccups and significant cash usage.
CVRx Shares Slide on Sales View Cut
CVRx shares dropped after the company announced a cut in its sales guidance. This adjustment in financial outlook indicates potential challenges or revised expectations for the company's performance.
CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution Disclosures
Johnson Fistel, PLLP is investigating CVRx, Inc. (CVRX) after the company significantly lowered its full-year revenue guidance to $58 million–$60 million, down from $63 million–$67 million. This reduction is attributed to challenges with sales-force execution, high turnover, and difficulties with onboarding and training new employees. The investigation also concerns a Department of Justice civil investigative demand regarding the company's sales and marketing practices.
CVRx Inc (CVRX) (Q2 2026) Earnings Call Highlights: Sales Execution Challenges Offset Strong ...
CVRx Inc (CVRX) reported Q2 2026 revenue of $15.7 million, up 16% year-over-year, with an 87% gross margin. However, the company lowered its full-year 2026 revenue guidance due to sales execution issues, including high sales force turnover and challenges with a major Medicare Advantage payer's AI-based prior authorization tools. CVRx is implementing a multi-pronged approach to address sales challenges, investing in training and new field roles, while confirming adequate cash reserves for at least 18 months.
[10-Q] CVRx, Inc. Quarterly Earnings Report
CVRx, Inc. filed its unaudited interim quarterly report (Form 10-Q) for the period ended June 30, 2026. The report details the company's financial position, including $60.0 million in debt, $64.6 million in cash, and $49.2 million in remaining ATM equity issuance capacity. The company reported net losses of $14.0 million for the quarter and $27.2 million for the six months ended June 30, 2026, and is cooperating with a Department of Justice civil investigative demand related to potential False Claims Act violations.
CVRx Reports Second Quarter 2026 Financial and Operating Results
CVRx, Inc. announced its Q2 2026 financial results, reporting $15.7 million in total revenue, a 16% increase year-over-year, and a gross margin of 87%. Despite strong growth and a new Medicare Advantage coverage policy from Humana for its Barostim therapy, the company updated its full-year outlook due to fewer sales territories, lower sales force productivity, and challenges with a major payer. CVRx expects full-year 2026 revenue between $58.0 million and $60.0 million and reiterated confidence in its long-term fundamentals.
CVRx (NASDAQ: CVRX) grows Q2 2026 revenue but cuts outlook
CVRx, Inc. reported a 16% increase in Q2 2026 revenue to $15.7 million, primarily driven by U.S. heart failure sales, with gross profit rising to $13.7 million and gross margin improving to 87%. Despite this growth, the company posted a net loss of $14.0 million, an improvement from the previous year, and announced a new Medicare Advantage coverage policy for its Barostim therapy from Humana. However, CVRx cut its full-year 2026 revenue outlook and expects Q3 2026 revenue to be between $13.5 million and $14.5 million, citing headwinds from fewer sales territories, lower sales force productivity, and challenges with a large payer.
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14
Lake Street has reaffirmed its Buy rating for CVRx Inc (CVRX.US) and maintained its target price at $14. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
CVRx Inc (CVRX) Institutional Confidence
The article details the institutional confidence in CVRx Inc (CVRX), noting its current institutional shareholding score of 5.00, which ranks 107th in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion stands at 65.53%, a decrease of 19.00% quarter-over-quarter. Bill Nygren (OAKMX) is highlighted as the largest institutional shareholder despite an 81.97% decrease in holdings.
CVRx to Present at Canaccord Genuity’s 46th Annual Growth Conference
CVRx, Inc., a medical device company focused on neuromodulation solutions for cardiovascular diseases, announced its management team will present at Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026, at 1:00 p.m. ET. The presentation will discuss the company's Barostim technology, the first FDA-approved device using neuromodulation to alleviate heart failure symptoms. A live webcast and archived version will be available on CVRx's investor relations website.
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
CVRx, Inc. announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 1:00 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible for a limited time afterward. CVRx specializes in neuromodulation solutions for cardiovascular diseases, featuring its FDA-approved Barostim™ technology for heart failure patients.
CVRx presentation will stream live from Boston on Aug. 11
CVRx (NASDAQ: CVRX), a medical device company specializing in neuromodulation therapies for cardiovascular disease, announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 1:00 p.m. ET. A live webcast and archived replay of the presentation will be available on the company's investor relations website. The announcement includes historical context detailing past stock reactions to similar conference presentations.
CVRX|CVRx Inc|Price:4.870|Chg%:+0.130
This article provides a detailed financial overview of CVRx Inc. (CVRX), offering an all-in-one data dashboard for investors. It includes current stock performance, key financial summaries such as income statements, balance sheets, and cash flow statements, and upcoming earnings dates. The report highlights the company's revenue, EPS, net profit, and various financial ratios, along with an analyst rating of "BUY".
